A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
The Indiana General Assembly is back in session and set to consider all manner of health care legislation, from consumer rights to expanded insurance coverage.
As IPL ditches coal in favor of natural gas at power plants in Indianapolis and Martinsville, the utility wants to close their coal ash pits, cover the tops with plastic membranes, and top them off with nearly three feet of sand and soil.
Gov. Mike Pence’s chief of staff, who will lose his position when Pence leaves office on Monday, is seeking to return to the five-member state commission that oversees utilities.
Alex Azar, president of Lilly USA LLC since 2012, is leaving the company just as his unit is about to lose a huge swath of sales personnel. The drugmaker announced a series of changes Thursday under new CEO David Ricks.
Departing Indiana Attorney General Greg Zoeller wants to persuade the organization to add Indianapolis to its roster of world trade centers, hooking local firms into international business networks and encouraging imports and exports.
Riley is spending millions of dollars and beefing up its emergency staff to expand into traditional emergency services.
Federal prosecutors say two American Senior Communities executives and two other men orchestrated a scheme that used kickbacks and shell companies to defraud American Senior Communities and federal health care programs out of millions of dollars.
In July, the U.S. Department of Justice sued the two companies to keep them independent. A trial got underway in November with no end in sight.
What’s driving the tiny hospitals here and around the country is cost. They’re often only 15,000 to 50,000 square feet in size and cost only $7 million to $30 million to build.
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
The Hoosier state still has an armful of health challenges, from high levels of smoking and obesity to the prevalence of air pollution and cardiovascular disease.
The “toxic” office environment at a small St. Vincent Health office had broken out during an unprecedented wave of acquisitions of physician practices in central Indiana.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
A new report by the Centers for Disease Control and Prevention is pushing states with high Medicaid smoking rates to do more to encourage enrollees to quit and live longer.
An Indiana state official in charge of regulatory oversight of nursing homes and residential care facilities has been barred from taking a job at a private company that runs senior living communities over ethics concerns.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
